|38.02||+1.08||+2.92%||Vol 10.15M||1Y Perf -15.49%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||-0.02 -0.05%|
|Target Price||49.14||Analyst Rating||Strong Buy 1.46|
|Potential %||29.25||Finscreener Ranking||★ 40.97|
|Insiders Trans % 3/6/12 mo.||-100/-100/-96||Value Ranking||★ 40.72|
|Insiders Value % 3/6/12 mo.||-100/-100/-98||Growth Ranking||★★ 45.10|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-97||Income Ranking||— -|
|Price Range Ratio 52W %||24.29||Earnings Rating||Sell|
|Market Cap||54.35B||Earnings Date||26th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Jul 2022|
|Estimated EPS Next Report||0.43|
|EPS Growth Next 5 Years %||10.80|
|Avg. Weekly Volume||10.29M|
|Avg. Monthly Volume||8.24M|
|Avg. Quarterly Volume||8.22M|
Boston Scientific Corporation (NYSE: BSX) stock closed at 38.02 per share at the end of the most recent trading day (a 2.92% change compared to the prior day closing price) with a volume of 10.15M shares and market capitalization of 54.35B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 38000 people. Boston Scientific Corporation CEO is Michael F. Mahoney.
The one-year performance of Boston Scientific Corporation stock is -15.49%, while year-to-date (YTD) performance is -10.5%. BSX stock has a five-year performance of 35.3%. Its 52-week range is between 34.98 and 47.495, which gives BSX stock a 52-week price range ratio of 24.29%
Boston Scientific Corporation currently has a PE ratio of 67.90, a price-to-book (PB) ratio of 3.08, a price-to-sale (PS) ratio of 4.23, a price to cashflow ratio of 33.80, a PEG ratio of 2.32, a ROA of 2.39%, a ROC of 4.77% and a ROE of 4.65%. The company’s profit margin is 6.66%, its EBITDA margin is 20.90%, and its revenue ttm is $12.16 Billion , which makes it $8.51 revenue per share.
Of the last four earnings reports from Boston Scientific Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.43 for the next earnings report. Boston Scientific Corporation’s next earnings report date is 26th Jul 2022.
The consensus rating of Wall Street analysts for Boston Scientific Corporation is Strong Buy (1.46), with a target price of $49.14, which is +29.25% compared to the current price. The earnings rating for Boston Scientific Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Boston Scientific Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Boston Scientific Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.81, ATR14 : 1.12, CCI20 : -18.52, Chaikin Money Flow : -0.03, MACD : -1.05, Money Flow Index : 47.24, ROC : -3.94, RSI : 48.00, STOCH (14,3) : 56.51, STOCH RSI : 1.00, UO : 55.75, Williams %R : -43.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Boston Scientific Corporation in the last 12-months were: Arthur C. Butcher (Option Excercise at a value of $143 843), Arthur C. Butcher (Sold 19 942 shares of value $43 990 605 ), Daniel J. Brennan (Option Excercise at a value of $848 285), Daniel J. Brennan (Sold 85 534 shares of value $3 688 993 ), David A. Pierce (Option Excercise at a value of $348 663), David A. Pierce (Sold 65 830 shares of value $2 681 703 ), David S. Wichmann (Buy at a value of $1 049 450), Edward F. Mackey (Option Excercise at a value of $0), Eric Francis Yves Thepaut (Option Excercise at a value of $261 600), Eric Francis Yves Thepaut (Sold 41 741 shares of value $1 842 305 ), Ian T. Meredith (Option Excercise at a value of $0), Ian T. Meredith (Sold 13 606 shares of value $591 012 ), Jeffrey B. Mirviss (Option Excercise at a value of $0), Jeffrey B. Mirviss (Sold 45 458 shares of value $2 051 445 ), Jodi Euerle Eddy (Option Excercise at a value of $175 396), Jodi Euerle Eddy (Sold 17 037 shares of value $756 117 ), John Bradley Sorenson (Option Excercise at a value of $0), John Bradley Sorenson (Sold 13 167 shares of value $568 816 ), Jonathan Monson (Option Excercise at a value of $0), Joseph M. Fitzgerald (Option Excercise at a value of $883 043), Joseph M. Fitzgerald (Sold 210 980 shares of value $9 494 754 ), Maulik Nanavaty (Option Excercise at a value of $0), Meghan Scanlon (Option Excercise at a value of $324 229), Meghan Scanlon (Sold 13 850 shares of value $623 389 ), Michael F. Mahoney (Option Excercise at a value of $6 679 310), Michael F. Mahoney (Sold 1 005 209 shares of value $44 165 983 ), Scott Olson (Option Excercise at a value of $0), Scott Olson (Sold 4 200 shares of value $181 776 ), Vance R. Brown (Option Excercise at a value of $0), Wendy Carruthers (Option Excercise at a value of $0), Wendy Carruthers (Sold 49 928 shares of value $2 121 954 )
Tue, 24 May 2022 09:55 GMT Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alcon (ALC)- TipRanks. All rights reserved.
Fri, 29 Apr 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Dexcom (DXCM)- TipRanks. All rights reserved.
Thu, 03 Mar 2022 07:46 GMT What Do Boston Scientifics Risk Factors Tell Investors- TipRanks. All rights reserved.
Fri, 11 Feb 2022 09:54 GMT Boston Scientific (BSX) Receives a Hold from Leerink Partners- TipRanks. All rights reserved.
Mon, 24 Jan 2022 06:36 GMT Boston Scientific (BSX) Gets a Hold Rating from Deutsche Bank- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.